Ranitidine in a twice daily triple therapy regimen for the eradication of Helicobacter pylori.
Harris
A
A
D000658:Amoxicillin / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D000994:Antitrichomonal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000209:etiology / Q000517:prevention & control*; D005753:Gastric Mucosa / Q000382:microbiology / Q000473:pathology; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects*; D006635:Histamine H2 Antagonists / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D006801:Humans; D008795:Metronidazole / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D010406:Penicillins / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D011899:Ranitidine / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D012008:Recurrence; D016896:Treatment Outcome
D000994:Antitrichomonal Agents; D006635:Histamine H2 Antagonists; D010406:Penicillins; D008795:Metronidazole; D000658:Amoxicillin; D011899:Ranitidine